Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NOSIP promotes cell proliferation and motility by targeting SPTAN1 for ubiquitination and degradation in clear cell renal cell carcinoma.

Scientific reports·2026
Same author

Large scale evaluation of a multiple tumor marker panel for lung cancer diagnosis and histological subtyping.

Discover oncology·2026
Same author

A cell motility-based selective hydrogel enables rapid generation of nerve-repairing blood clots.

Bioactive materials·2026
Same author

FBXO31-induced ABL2 ubiquitination increases cystine-glutamate antiporter-mediated ferroptosis and inhibits malignant progression in triple-negative breast cancer.

American journal of translational research·2026
Same author

Dyadic effects of role adaptation on postpartum anxiety and depression: the mediating role of future time insight and parenting competence.

BMC psychiatry·2026
Same author

High Prevalence of Cronobacter in Spices and Emergence of Multidrug-Resistant Salmonella in Retail Foods, Northwest China (2020-2024).

Journal of food protection·2026
Same journal

A "three-in-one" nose-to-brain delivery strategy: intranasal vancomycin spray achieves simultaneous clearance of pneumococcal colonization, bacteremia, and meningitis.

International journal of pharmaceutics·2026
Same journal

10-Hydroxy-2-decenoic acid /matrine deep eutectic solvent encapsulated in hyalurosomes for enhanced transdermal delivery and antioxidant efficacy.

International journal of pharmaceutics·2026
Same journal

Dual-trigger hyaluronic acid nanoprodrug incorporating a 2-nitrobenzenesulfonyl linker for CD44-targeted and glutathione-responsive drug delivery.

International journal of pharmaceutics·2026
Same journal

Polymeric mixed micellar nanogel enhances dermal delivery and therapeutic efficacy of tofacitinib citrate.

International journal of pharmaceutics·2026
Same journal

Localized gold nanoparticles-mediated photothermal therapy for head and neck cancer: in vivo proof-of-concept.

International journal of pharmaceutics·2026
Same journal

Design and evaluation of a pump-free ultrasonic atomization-driven hollow microneedle array for transdermal drug delivery.

International journal of pharmaceutics·2026
See all related articles

Related Experiment Video

Updated: May 21, 2025

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology
05:21

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology

Published on: May 16, 2022

2.8K

Innovative centrifugal microfluidic approach for risperidone-loaded PLGA microsphere production.

Bingwen Zhang1, Haofan Liu2, Yixuan Li3

  • 1College of Quality and Technical Supervision, Hebei University, Baoding, China.

International Journal of Pharmaceutics
|March 18, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces centrifugal microfluidic technology for creating risperidone-loaded poly(lactic-co-glycolic acid) microspheres. Optimized microspheres offer stable drug release for up to 42 days, showing potential for long-acting schizophrenia therapy.

Keywords:
Centrifugal microfluidicsDrug delivery systemsPLGA microspheresRisperidone

More Related Videos

Author Spotlight: Advancing Therapeutics with Biocompatible Sodium Alginate Hydrogel Microspheres
07:24

Author Spotlight: Advancing Therapeutics with Biocompatible Sodium Alginate Hydrogel Microspheres

Published on: June 7, 2024

1.6K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.1K

Related Experiment Videos

Last Updated: May 21, 2025

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology
05:21

Fabricating Highly Open Porous Microspheres HOPMs via Microfluidic Technology

Published on: May 16, 2022

2.8K
Author Spotlight: Advancing Therapeutics with Biocompatible Sodium Alginate Hydrogel Microspheres
07:24

Author Spotlight: Advancing Therapeutics with Biocompatible Sodium Alginate Hydrogel Microspheres

Published on: June 7, 2024

1.6K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.1K

Area of Science:

  • Pharmaceutics
  • Biomaterials Science
  • Microfluidics

Background:

  • Microsphere drug delivery systems are crucial for sustained therapeutic effects.
  • Developing efficient and scalable methods for microsphere preparation remains a challenge.
  • Risperidone is a key antipsychotic medication requiring optimized delivery for chronic conditions like schizophrenia.

Purpose of the Study:

  • To develop and optimize a novel centrifugal microfluidic technology for preparing risperidone-loaded poly(lactic-co-glycolic acid) microspheres (RIS-MS).
  • To evaluate the impact of key preparation parameters on RIS-MS characteristics.
  • To assess the in vivo pharmacokinetics and sustained release profile of RIS-MS.

Main Methods:

  • Utilized centrifugal microfluidic technology for RIS-MS fabrication.
  • Investigated parameters such as PLGA concentration, microchannel diameter, and centrifugal speed.
  • Performed in vivo pharmacokinetic studies in rabbits and analyzed drug release profiles.

Main Results:

  • Successfully produced RIS-MS using microchannels (170-210 μm) at 400 rpm with ≥15% PLGA.
  • Achieved more stable plasma concentrations and a lower Cmax compared to risperidone suspension.
  • Demonstrated sustained release of risperidone for up to 42 days in rabbits.

Conclusions:

  • Centrifugal microfluidic technology offers an efficient method for producing high-quality RIS-MS.
  • Optimized RIS-MS exhibit excellent sustained-release properties.
  • These RIS-MS hold significant potential for long-acting injectable therapy in schizophrenia management.